Development interruptions caused by accidents, disasters or infectious diseases at outsourced partners and research facilities
First written in FY2021. 3 of 4 entries say "Restated". Latest entry: FY2025.
4 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Unforeseen events at contractors, such as natural disasters or outbreaks of serious infectious diseases, may disrupt the stable supply of drug substances, prevent the Company from receiving services in a timely manner, or delay research and development activities, including clinical trials.」
This reconfirms the risk that disasters, infectious diseases and other events affecting external contractors may delay the supply of drug substances, services, clinical trials and research and development. - FY2023RestatedAnnual report
「Unforeseen events at contractors, such as natural disasters or outbreaks of serious infectious diseases, may disrupt the stable supply of drug substances, prevent the Company from receiving services in a timely manner, or delay research and development activities, including clinical trials.」
This reconfirms the risk that disasters, infectious diseases and other events affecting external contractors may delay the supply of drug substances, services, clinical trials and research and development. - FY2022RestatedAnnual report
「The Company's relationships with its contractors are currently good, and it intends to continue doing business with them. However, unforeseen events at contractors, such as natural disasters or outbreaks of serious infectious diseases, may disrupt the stable supply of drug substances, prevent the Company from receiving services in a timely manner, or delay research and development activities, including clinical trials.」
This reconfirms the risks of supply stoppages, service delays and research and development delays involving external contractors such as CROs, clinical trial facilities and manufacturers. - FY2021First statedAnnual report
「If natural disasters such as earthquakes or floods, or other difficult-to-avoid events, occur at the Company or its external contractors, causing equipment or infrastructure to become unusable, employees and others to be unable to report to work, or operations to be suspended temporarily or for an extended period, and consequently requiring clinical development to be suspended temporarily or for an extended period, the Company's operating results and financial position may be affected.」
This addresses the risk of business interruption and suspension of clinical development at both the Company's own facilities and external contractors, including CROs, clinical trial facilities and manufacturers.